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Abstract
Objective: An adverse effect of acid-suppression medications on the occurrence of Clostridium difficile infection (CDI) has
been a common finding of many, but not all studies. We hypothesized that association between acid-suppression
medications and CDI is due to the residual confounding in comparison between patients with infection to those without,
predominantly from non-tested and less sick subjects. We aimed to evaluate the effect of acid suppression therapy on
incidence of CDI by comparing patients with CDI to two control groups: not tested patients and patients suspected of
having CDI, but with a negative test.
Methods: We conducted a case-control study of adult patients hospitalized in internal medicine department of tertiary
teaching hospital between 2005–2010 for at least three days. Controls from each of two groups (negative for CDI and non-
tested) were individually matched (1:1) to cases by primary diagnosis, Charlson comorbidity index, year of hospitalization
and gender. Primary outcomes were diagnoses of International Classification of Diseases (ICD-9)–coded CDI occurring
72 hours or more after admission.
Results: Patients with CDI were similar to controls with a negative test, while controls without CDI testing had lower clinical
severity. In multivariable analysis, treatment by acid suppression medications was associated with CDI compared to those
who were not tested (OR=1.88, p-value=0.032). Conversely, use of acid suppression medications in those who tested
negative for the infection was not associated with CDI risk as compared to the cases (OR=0.66; p=0.059).
Conclusions: These findings suggest that the reported epidemiologic associations between use of acid suppression
medications and CDI risk may be spurious. The control group choice has an important impact on the results. Clinical
differences between the patients with CDI and those not tested and not suspected of having the infection may explain the
different conclusions regarding the acid suppression effect on CDI risk.
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Background
The morbidity and mortality rates caused by Clostridium
difficile have increased lately, reflecting increased antibiotic use,
the aging population and the emergence of high-level resistant
strains [1,2] Outbreaks of CDI have been registered in hospitals
worldwide [1,3], with reports of increased severity of disease, more
frequent community acquired disease and rising CDI-associated
healthcare costs [4,5]. The Centers for Disease Control (CDC)
have reported that the annual burden of CDI in the US is.
350,000 new cases with 14,000 CDI-related deaths. [6]
Antibiotic treatment has been shown to be the main risk factor
for development of CDI. [6,7] Additional, well-established, risk
factors include advancing age (e.g. older than 65), hospital
admission, severe underlying disease, [8] prolonged hospitalization
[9] and invasive gastrointestinal procedures. [10]
During the last decade studies have reported marked overuse of
proton pump inhibitors (PPIs). As many as 60% of prescriptions
may not follow the criteria of the National Institute for Clinical
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reasons [11–13]. Gastric acid suppression treatment has been
shown repetitively to be associated with an increased risk of
hospital and community-acquired CDI. [14–18]. This association
has been explained by the loss of the defensive effect of gastric
acid. [12,19] While this mechanism appears reasonable for
vegetative enteric pathogens it is less plausible for CDI where
the inoculum is believed to be predominantly in the form of acid-
resistant spores. Also, the association between acid suppression
therapy and CDI has not been universal and was not found in
some studies. [12,20]
One of the major limitations of these pharmaco-epidemiological
studies is a potential bias inherently associated with this type of
analysis: despite the multivariate adjustment the two comparison
groups (with and without acid suppression) might differ signifi-
cantly. Patients who develop CDI are known to be more ill than
most other hospital patients. Thus they may be more likely to
carry risk factors and exposures that lead to the use of acid
suppression therapy. Put differently, the epidemiologic association
may result from severe underlying disease being associated with
CDI and, in parallel, leading to increased PPI use.
We hypothesize that the comparison groups used to examine
the association between acid suppression therapy and CDI are
intrinsically unsuited due to their very different clinical character-
istics leading to bias. Therefore, to address this concern, we
conducted a nested case-control study of CDI patients with two
separate matched control groups: one with suspected CDI but
negative stool testing and a second without suspected CDI.
Methods
Study Population and Study Groups Definition
The study population comprised adult patients hospitalized in
internal medicine wards of Soroka University Medical Center
(SUMC) during the period 2005–2010. SUMC is a 1100-bed
tertiary teaching hospital and the only provider of in-hospital care
for the population of 700,000 in southern Israel. Patients included
in the study had to spend at least 3 days in the hospital and cases
had to be hospitalized 3 days before infection was detected (to
qualify as a hospital-acquired infection). We chose not to include
patients hospitalized after 2010 in light of growing awareness in
our hospital of the reported risk of CCDI associated with use of
acid-suppressor medications, supported by the FDA safety
announcement issued in Feb 2, 2012 [21].
Cases were defined as a first incidence of a positive stool C.
difficile toxin (by enzyme-linked immunosorbent assay) in a
patient with diarrhea. For each case we matched one control with
a negative C. difficile toxin test and one who was not suspected to
have CDI and was not tested. Both types of controls were matched
by gender, age (with a caliper of 5 years) and hospitalization within
12 months before or after the date of the case hospitalization.
Controls with a negative test for CDI were also matched by the
primary diagnosis.
Definitions
Treatment by acid-suppressors was defined as use of a H2
receptor antagonist (H2RA) or PPI three months prior to
admission and during the index hospitalization. The H2RA
medications included famotidine and ranitidine; PPI medications
included omeprazole, lansoprazole and pantoprazole. We further
defined exposure to acid suppression by three levels of intensity: (a)
patients not receiving acid-suppressor medications, (b) patients
receiving only H2RA medications, and (c) patients receiving one
daily dose of PPI treatment.
Antibiotic treatment was defined by the extent of exposure to
antibiotics and was analyzed in 3 groups by the expected risk of
CDI: i.e. no antibiotics administered, low-risk and high- interme-
diate risk antimicrobials. The group of high-intermediate risk
antibiotics included fluoroquinolones, cephalosporins, beta-lac-
tams, macrolides, carbapenems, sulfonomides and clindamycin.
All other types of antibiotics were included in the low-risk
category. This breakdown of antibiotics medications follow the
definitions set in our previous investigation [22], as well as by
UpToDate web site [23].
Primary diagnosis and co-morbidities were defined by the
International Classification of Diseases, 9th Revision (ICD-9). We
used the Charlson index to compute the burden of co-morbid
conditions. The overall comorbidity score reflects the cumulative
increased likelihood of one-year mortality; the higher the score,
the more severe the burden of comorbidities. [24]
No informed consent was required, as the current research was
based only on patients’ medical records collected from the hospital
admission-discharge-transfer (ATD) database. Patients’ records
were anonymized and de-identified prior to analysis. This
approach, as well as the protocol of the study, has been approved
by the Soroka University Medical Center IRB committee.
Statistical Analysis
Continuous variables were presented as means6standard
deviation (sd), median, minimum and maximum; they were
compared between study groups using Wilcoxon and t-test,
depending on the variable distribution. Categorical variables were
presented as percent out of available cases and compared between
study groups using univariate conditional logistic regression
technique. Cases were compared separately to each type of
control. Multivariate analysis for identifying independent factors
affecting CDI was performed using conditional logistic regression.
We restricted the study population in the multivariable analysis to
those cases with matched controls to keep the comparisons
balanced. We performed sensitivity analysis on a sub-set of the




During the study period (2005–2010) the SUMC laboratory
tested 2,343 stool samples for CDI, 337 were positive (Figure 1)
and 212 out of 337 were found eligible for the study (main reasons
for non-eligibility were: hospital stay shorter than 72 hours, age
below 18, not primary case of CDI). There were 185 patients with
a negative stool test and 159 patients without a test who could be
matched to the cases. Both types of controls were matched only to
132 cases.
The study population
Approximately half of the patients were women (51.4%) and on
average 69 years old (Table 1). As matching by age was performed
with a caliper of 5 years, there was a small discrepancy in age
between the study groups; controls with a negative test result were
one year older and controls without a test were 2 years older
compared to their cases. Even though being clinically marginally
important, the two-years difference in age between cases and the
controls without a test was statistically significant (p-value,0.001).
Of note, 19.3% of the CDI patients lived in nursing homes,
compared to 10.8% in the 2 groups of controls (p-value=0.042).
Treatment by antibiotics was more intense within the CDI group
than in patients without CDI (Table 2).
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not different between the study groups. The majority of patients
were hospitalized due to an infectious disease (62.8%), followed by
17.3% with a diagnosis of a cardiovascular disorder and 9.4%
patients hospitalized due to a neoplasm. The group of CDI cases
was similar to the group of controls with a negative C. difficile test
by their co-morbidities and Charlson score (Table 3). Controls
without a test had significantly lower rates of pneumonia and
anemia (p-value=0.030 and p-value,0.001, respectively). The
proportion of patients fed by nasogastric tube was similar in CDI
cases (25.5%) and in controls with a negative test (31.9%) but was
lower in control patients without a test (12.6%). To summarize,
patients with CDI were similar to controls with a negative test,
while controls without a suspicion for CDI had lower clinical
severity in several respects. These clinical differences were
reflected in a longer hospitalization and higher mortality rate
within the patients with a test compared to the patients without
(median length of stay was 15 days and 1-year mortality rate
reached 49.6% in the group with the test (controls and cases),
compared to 5 days of stay (p-value,0.001) and mortality rate
37.7% (p-value=0.11) in the group without the test.
Acid suppression therapy
Treatment by acid-suppression medication prior to hospitaliza-
tion was recorded in 38% patients, without differences between
the study groups (table 4). However, as we noticed previously with
clinical characteristics, the frequency of treatment by acid
suppression medications was similar between cases and controls
with a negative test but different from the controls without a test.
Administering of H2RA was more common within patients with a
C. difficile test, 21.7% and 20.0% for those with a positive or
negative result, respectively, compared to 13.8% for those with no
test. In other words, CDI cases were not different from the controls
suspected for having CDI (and thus tested) in terms of their
exposure to H2RA (p-value=0.511), but their exposure to H2RA
was higher compared to the controls without a test (at borderline
significance level of 0.074). Of note, exposure to PPI therapy was
more frequent within those who tested negative for CDI than in
the group of CDI cases (48.6% vs. 36.8%, p-value=0.004).
Results of a multivariable analysis of factors associated with the
C.Difficile infection are presented in table 5. After adjusting for
well-established risk factors, i.e. Charlson index, residence in a
nursing home and treatment by antibiotics, treatment by acid
suppression medications showed a protective trend on risk for CDI
(OR=0.66; p-value=0.059) within the group of patients suspect-
ed for infection (i.e. tested for CDI). However, as reported by other
studies, treatment with these medications was associated with an
increased likelihood of the infection when CDI cases were
compared to the controls that were not tested (OR=1.88, p-
value=0.032). Similar trends were obtained for the effect of
H2RA and PPI medications, when tested separately. Treatment by
H2RA showed no risk increase whereas the administration of a
PPI significantly reduced the likelihood of CDI within the patients
who were tested (OR=0.54; p-value=0.019). Each medication
was associated with an increased likelihood of CDI when CDI
cases were compared to untested controls, however with p-values
approaching significance (ORH2RA=1.99, p-value=0.075 and
ORPPI=1.82, p-value=0.077).
Sensitivity and Missing Data Analysis
Not all 212 CDI cases were matched to both types of controls.
Sensitivity analysis on a fully matched set of 132 cases with both
controls available showed no difference in study conclusions.
Furthermore, 27 CDI cases had no tested negative controls and
53 CDI had no controls from the group without a test. Closer
inspection of distribution of exposure within ‘‘not-paired’’ CDI
cases reveal that 27 cases without negative tested controls to the
rest of the sample used in the analysis. However, 53 cases without
a match in non-suspected group had lower exposure to acid-
suppression therapy (47% in non-paired cases vs. 62% in the
paired cases used in the main analysis). We have simulated a
univariable conditional logistic regression analysis on 1000
samples assuming inclusion of the group of unpaired cases, which
would have resulted in overall 58.2% of exposure in all cases. The
analysis showed that the risk estimate would have decreased from
Figure 1. Flowchart of enrolled patients.
doi:10.1371/journal.pone.0110790.g001
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significance.
Discussion
In this study we hypothesized that the comparison of CDI cases
to all hospital patients without CDI, as adopted in a majority of
studies, brings bias to the results based on the overall severity of
illness in the CDI patients. Severely ill patients may be more likely
to receive acid suppression medications leading to an apparent
association of these medications with CDI. We assessed our
hypothesis in a case-control setting, in which patients with a
positive test for C. difficile (CDI cases) were compared separately
to patients suspected of CDI but with a negative test (a group that
may be clinically more similar to CDI patients) and controls in
whom CDI was not suspected or tested for.
The data obtained in our study brought us to a different
understanding of the association between acid-suppression med-
ications and CDI. From the comparison of demographical, clinical
and procedural characteristics of the study groups – it became
apparent that the group of cases is similar to the group of controls
with suspected CDI but having a negative test. Furthermore, both
are very different from the patients without a test. The CDI cases
and the controls with a negative test are united by a clinical
suspicion for having CDI (and therefore being tested for it). This
clinical suspicion identifies a group of subjects with high
underlying disease burdens and high subsequent death rates.
The similarity between CDI cases and controls with a negative test
for CDI and their difference from patients not suspected of CDI is
statistically evident for the diagnoses of pneumonia and/or
anemia, more prevalent co-morbidities, as well as more frequent
procedures compared to patients in whom the test was not
Table 1. Demographic Characteristics of the Study Population.
Demographic characteristics
Cases: Patients testing positive for C.
difficile (N=212) Patients without C. difficile infection
Patients negative on C. difficile test -
Controls type 1 (N=185)
Patients without a C. difficile test -
Controls type 2 (N=159)
Age, years
Mean6SD 68.2616. 9 69.0616.9 71.2617.5
Median 72.0 74.0 77.0
Min; Max 18.0–92.0 18.0–92.0 22.0–97.0
(pv vs. cases) (pv=0.084) (pv,0.001)
Female Gender, % (n/N) 53.3% (112) 55.7% (103) 51.6% (82)
(pv vs. cases) (pv=1.000) (pv=1.000)
Family status, %(n/N)
Married 62.5%(130/208) 58.3%(98/168) 58.5%(93)
Divorced 3.4%(7/208) 5.4%(9/168) 3.8%(6)
Widow 9.1%(19/208) 7.7%(13/168) 12.6%(20)
Not Married 7.2%(15/208) 7.1%(12/168) 7.5%(12)
(pv vs. cases) (pv=1.000) (pv=0.330)
Country of birth, %(n/N)
Israel 21.2%(45) 19.5%(36) 20.8%(33)
Former USSR 25.0%(53) 25.4%(47) 30.2%(48)
Asia 33.5%(71) 28.6%(53) 23.9%(38)
Europe 7.5%(16) 9.2%(17) 19.5%(31)
North America 4.7%(10) 4.3%(8) 1.9%(3)
Africa 4.7%(10) 2.7%(5) 3.1%(5)
(pv vs. cases) (pv=0.143) (pv=0.596)
Residence %(n/N)
Home 78.3%(166) 86.5%(160) 86.8%(138)
Nursing Home 19.3%(41) 10.3%(19) 11.3%(18)
Other 2.4%(5) 3.2%(7) 1.9%(3)
(pv vs. cases) (pv=0.087) (pv=0.143)
Type of Residency, %(n/N)
City 79.4%(167) 75.8%(138) 85.8%(133)
Non-urban settlement 7.1%(15) 7.0%(13) 7.0%(11)
Kibbutz 3.8%(8) 1.6%(3) 3.9%(6)
Bedouin-Arab village 8.1%(17) 6.6%(12) 4.5%(7)
(pv vs. cases) (pv=0.132) (pv=0.067)
doi:10.1371/journal.pone.0110790.t001
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required nasogastric feeding and more frequently had a positive
bacterial culture in blood, sputum or urine, compared to controls
without a CDI test. These markers of increased underlying disease
severity were also associated with adverse clinical outcomes
including longer hospitalizations and higher mortality rates.
Prior exposures to acid-suppressing medications in the commu-
nity was not different between the study groups, but changed
following hospitalization, when patients not suspected of having
CDI were less likely to receive acid-suppressing medication
compared to those with suspected or proven CDI. This
discrepancy resulted in an estimated independent adverse effect
for exposure to H2RA and PPI medications, with OR=1.88 (p-
value=0.032) for those with CDI compared to the controls that
were not tested. Quite remarkably, the patients with a negative C.
difficile test were more likely to be exposed to intensive acid
suppression treatment (48.6% exposed to PPI) compared to those
with CDI (36.7% exposed to PPI). In keeping with this finding, the
multivariable analysis did not show a detrimental effect of acid
suppression medications (OR=0. 66, p-value=0.059) in compar-
ison between patients with CDI and those with suspected CDI.
Based on the contradictory findings we cannot conclude that there
is an adverse effect of exposure to acid-suppressing medication and
CDI risk.
Acid anti-secretory medications and particularly PPIs may lead
to diarrhea. [25] Thus, patients taking PPIs may be more likely to
be tested for CDI but be negative, as most of the patients would
have PPI-induced diarrhea, in comparison to general population
of patients with more prevalent CDI-induced diarrhea. To
illustrate this let us consider the following hypothetical example,
where we have 100 patients with diarrhea and no PPI treatment
with CDI prevalence of 5% (5 cases); and let us assume that PPI
treatment is associated with 2 folds increase in diarrhea risk,
leading to a situation where in the same hospital population, but
now treated with PPI we will have twice as many patients with
diarrhea – 200. Assuming that PPI treatment does not increase
CDI risk, among these 200 subjects we will still have the same 5
cases of CDI (2.5%). We might conclude that statistically speaking
PPI treatment is associated with a protective effect against CDI – a
decrease from 5% to 2.5% incidence. This may, in part, account
for the protective, but spurious PPI effect observed in our study.
Our findings disagree directly with the widely held opinion that
acid suppression medications are a risk factor for CDI. This
discrepancy inevitably leads to questions regarding the validity of
Table 2. Clinical Characteristics of the study population during hospitalization, by study groups.
Clinical Characteristics
Cases: Patients testing
positive for C. difficile
(N=212) Patients without C. difficile infection
Patients negative on C. difficile
test - Controls type 1 (N=185)
Patients without a C. difficile test -
Controls type 2 (N=159)
Procedure during Hospitalization, % (n)
(pv vs. cases)
Colonoscopy 6.1% (13) 7.1%(13) (pv=1.000) 2.5%(4) (pv=0.092)
Surgery 22.9% (47/205) 28.2%(51/181) (pv=0.590) 3.8%(6) (pv,0.001)
Feeding, %(n)
Oral 71.2% (151) 67.6%(125) 85.6%(136)
Nasogastric tube 25.5% (54) 31.9%(59) 12.6%(20)
PEG 3.3% (7) 0.5%(1) 1.9%(3)
(pv vs. cases) (pv=0.925) (pv=0.003)
Antibiotics 3 months prior to or during
hospitalization, % (n) (pv vs. cases)
96.7% (205) 91.9% (170) (pv=0.064) 66.0% (105) (pv,0.001)
Before Hospitalization 45.8% (97) 20.0% (37) (pv,0.001) 19.5% (31) (pv,0.001)
During Hospitalization 93.4% (198) 88.1% (163) (pv=0.151) 64.2% (102)(pv,0.001)
WBC
Mean6SD 15.7618.6 11.967.9 11.667. 7
Positive result obtained for test in, % (n)
(pv vs. cases)
Bacteriology 54.7%(116) 48.1%(89) (pv=0.271) 25.3%(40) (pv,0.001)
Blood 19.3% (41) 23.8% (44) (pv=0.499) 9.4% (15) (pv=0.002)
Sputum 9.1% (19) 11.4%(21) (pv=0.398) 0.6% (1) (pv,0.001)
Urine 40.6%(86) 27.5%(51) (pv=0.014) 14.5%(23) (pv,0.001)
Length of stay, days
Median 16.0 13.0 5.0
Min-Max 0.0–440.0 1.0–127.0 (pv=0.078) 1.0–69.0 (pv,0.001)
Mortality, %(n) (pv vs. cases)
In-hospital 21.2% (45) 18.4%(34) (pv=0.409) 13.2%(21) (pv=0.010)
At 1 year follow-up 53.3%(113) 45.4%(84) (pv=0.110) 37.7%(60) (pv,0.001)
doi:10.1371/journal.pone.0110790.t002
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difficile tests might have concealed the effect. However, the
assessed effect is in fact significantly opposite, which cannot be
fully explained by laboratory error. Our results showing an
adverse effect of acid-suppression medications in comparison with
controls not tested for CDI, is in fact, consistent with the published
research by Pohl [18], Howell et al [22], Bavishi and Dupont [26]
or by Pakyz et al [27], where the control group consisted of all
Table 3. Clinical Characteristics of the study population at admission, by study groups.
Clinical Characteristics
Cases: Patients testing
positive for C. difficile (N=212) Patients without C. difficile infection
Patients negative on C. difficile
test - Controls type 1 (N=185)
Patients without a C. difficile test -
Controls type 2 (N=159)
Primary Diagnosis, % (n)
Cardiovascular 16.5% (34) 17.8% (33) 18.2% (29)
Infectious 67.0% (142) 58.9% (109) 61.6% (98)
Neoplasm 8.0% (17) 11.4% (21) 8.8% (14)
Orthopedics 3.3% (7) 2.7% (5) 0.6% (1)
Renal 2.8 (6) 2.7% (5) 6.9 (11)
Others 2.8 (6) 6.5% (12) 3.8 (6)
(pv vs. cases) (pv=0.370) (pv=0.199)
Co-morbidities, % (n) (pv vs. cases)
History MI 19.8%(42) 27.6%(51) (pv=0.182) 25.2%(40) (pv=0.532)
Heart failure 43.3%(94) 40.5%(75) (pv=0.177) 40.3%(64) (pv=0.306)
Chronic Pulmonary Disease 8.0%(17) 8.6%(16) (pv=0.839) 11.3%(18) (pv=0.850)
Pneumonia 30.2% (17) 30.3% (56) (pv=1.000) 20.8% (33) (pv=0.030)
Diabetes 34.4%(73) 37.3%(69) (pv=1.000) 34.6%(55) (pv=0.810)
Hypertension 46.2%(98) 48.1%(89) (pv=0.644) 52.2%(83) (pv=0.550)
Chronic Renal Failure 13.7%(29) 14.1%(26) (pv=0.880) 13.2%(21) (pv=0.424)
Peptic Ulcer Disease 4.7%(10) 4.9%(9) (pv=1.000) 2.5%(4) (pv=0.344)
Cancer 19.3%(41) 26.5%(49) (pv=0.057) 19.5%(31) (pv=1.000)
Anemia 40.1%(85) 37.8%(70) (pv=1.000) 28.3%(43) (pv=0.001)
Charlson Index
Mean6SD 5.063.3 5.663.9 5.063.3
Median 5.0 6.0 5.0
Min-Max (pv vs. cases) 0.0–19.0 0.0–18.0 (pv=0.114) 0.0–15.0 (pv=0.520)
doi:10.1371/journal.pone.0110790.t003
Table 4. Exposure to Acid-suppression medications, by study groups.
Acid suppression medication
Cases: Patients testing
positive for C. difficile (N=212) Patients without C. difficile infection
Patients negative on C. difficile
test - Controls type 1 (N=185)
Patients without a C. difficile test - Controls
type 2 (N=159)
Acid suppression % (n/N)
Within 3 months prior to
hospitalization
H2RA 8.5% (18) 11.4% (21) (pv=0.275) 6.9% (11) (pv=0.283)
PPI 26.4% (56) 31.3% (58) (pv=0.223) 29.6% (47)(pv=0.892)
Acid suppression % (n/N)
During hospitalization 58.5% (124) 68.7% (127) (pv=0.041) 47.2% (75) (pv=0.008)
By type of medication (pv vs. cases)
H2RA 21.7% (46) 20.0%(37) (pv=0.511) 13.8%(22) (pv=0.074)
PPI 36.8% (78) 48.6%(90) (pv=0.004) 33.3%(53) (pv=0.222)
doi:10.1371/journal.pone.0110790.t004
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with a negative CDI test was diluted by the majority who were not
tested. Therefore, the published data parallels the results in our
study whereby untested controls show reduced use of acid
suppression medications compared to those with CDI. Of note,
few studies comparing cases to patients with negative CDI results,
e.g. by Shah et al in 2000 [28] or McFarland et al in 2007 [29],
found no association between exposure to acid-suppression and
the infection.
Previous research [30] and our data support the hypothesis that
the administration of acid-suppressors and testing for CDI
(whether positive or negative) are both markers of an unmeasured
severity of illness. Comparing cases and controls within a group of
patients with the test, who are similar in their degrees of disease
severity, could produce the level of adjustment needed to
unmeasured confounders. A cohort strategy might lack this
necessary level of adjustment and result in biased estimates.
Our analyses confirmed several well-established risk factors for
the development of CDI including antibiotic therapy and
residence in a nursing home. Conversely, in our study acid
suppression therapy was not associated with an increased risk for
CDI when patients with similar levels of disease severity were
compared. Acid suppression therapy and CDI both track patients
with more severe disease leading to an apparent association that
does not appear to be primary or causative. Furthermore, these
results draw into question the recent Drug Safety Labeling
Changes made by the US FDA warning about an association
between PPI use and risk for CDI as well as similar warnings in
current CDI treatment guidelines. [31]
The study findings, however, have to be treated with caution in
view of its limitations. Not all CDI cases were matched to both
types of controls; however sensitivity analysis on a fully matched
set (132 cases + 2 controls) did not changed conclusions from the
main analysis. Likewise, sensitivity analysis of cases without
negatively tested controls (27 cases) and cases without non-
suspected controls (53 cases) resulted in the same statistical
inference. These findings support the internal validity of the study.
We assume that some of the questionable findings in the study
may have roots in a possible bias, e.g. the spurious protective effect
of PPIs, as discussed previously. The positive effect of PPIs use
could have been inflicted by a synergistic interaction that becomes
prominent when antibiotics and PPIs are used together [32].
However, the interaction should not affect our findings since the
rates of the antibiotics exposure were similar in tested controls
(88.1%) and cases (93.4%).
The results might be not fully generalizable, as the study was
conducted in a single hospital. On the other hand, the point
estimates obtained throughout the analysis is within the range of
the effect reported in other studies, which supports the external
validity of the results.
To conclude, the potential study bias described in the current
analysis needs to be addressed in future research by a careful
selection of the relevant control groups for CDI patients.
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